Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) have received an average rating of “Moderate Buy” from the six ratings firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $14.8333.

KPTI has been the topic of a number of recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Karyopharm Therapeutics in a research note on Monday, December 29th. The Goldman Sachs Group set a $12.00 price target on Karyopharm Therapeutics in a research report on Wednesday, December 17th. Robert W. Baird decreased their price target on Karyopharm Therapeutics from $25.00 to $21.00 and set an “outperform” rating on the stock in a research note on Thursday, October 9th. Piper Sandler reissued an “overweight” rating and set a $12.00 price objective on shares of Karyopharm Therapeutics in a research note on Wednesday, December 17th. Finally, HC Wainwright raised shares of Karyopharm Therapeutics from a “neutral” rating to a “buy” rating and set a $15.00 target price on the stock in a research note on Monday, October 13th.

Karyopharm Therapeutics Price Performance

Shares of NASDAQ KPTI opened at $6.31 on Friday. The stock has a market capitalization of $115.54 million, a P/E ratio of -0.43 and a beta of 0.21. Karyopharm Therapeutics has a one year low of $3.51 and a one year high of $10.80. The firm’s 50 day simple moving average is $6.55 and its two-hundred day simple moving average is $5.92.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Monday, November 3rd. The company reported ($3.82) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.30) by ($0.52). The firm had revenue of $44.04 million for the quarter, compared to the consensus estimate of $39.56 million. As a group, equities analysts expect that Karyopharm Therapeutics will post -0.71 earnings per share for the current fiscal year.

Institutional Trading of Karyopharm Therapeutics

Institutional investors have recently modified their holdings of the company. Baird Financial Group Inc. purchased a new position in Karyopharm Therapeutics during the 2nd quarter valued at about $45,000. XTX Topco Ltd bought a new stake in shares of Karyopharm Therapeutics in the 2nd quarter worth approximately $56,000. Silverback Asset Management LLC increased its stake in shares of Karyopharm Therapeutics by 40.0% during the second quarter. Silverback Asset Management LLC now owns 70,000 shares of the company’s stock valued at $302,000 after buying an additional 20,000 shares during the period. ADAR1 Capital Management LLC bought a new position in shares of Karyopharm Therapeutics during the third quarter valued at approximately $164,000. Finally, Bank of America Corp DE raised its holdings in shares of Karyopharm Therapeutics by 26.8% during the second quarter. Bank of America Corp DE now owns 168,534 shares of the company’s stock valued at $726,000 after acquiring an additional 35,626 shares in the last quarter. 66.44% of the stock is currently owned by hedge funds and other institutional investors.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.